SynAct Pharma AB (the "Company") announces that the number of shares and votes has increased by 2,451,600 as a result of the directed share issue and conversion of warrants, which was carried out in July 2025.

Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 52,326,143. The total number of shares in the rights issue was 2,313,125, of which 1,447,500 shares were registered with the Swedish Companies Registration Office in July 2025. In the conversion of warrants during July, a total of 1,004,100 warrants were converted into shares, providing the company with SEK 17.7 million.

For further information, please contact:
Björn Westberg, CFO SynAct Pharma
Tel: +46 733 940 953
Email: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: https://synactpharma.com/.

This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-07-31 18:00 CEST.

Attachments
Change in number of shares and votes in SynAct Pharma AB

Läs mer på MFN